Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a traditional chinese granule ease a common cancer treatment side effect?

NCT ID NCT07355361

Symptom relief Sponsor: Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding Huaier Granule to standard care can reduce proteinuria (excess protein in urine) in breast cancer patients who developed it as a side effect of immunotherapy or anti-angiogenic therapy. About 120 women will be randomly assigned to receive either standard care alone or standard care plus Huaier Granule for up to 24 weeks. The main goal is to see if the combination improves proteinuria treatment response after 8 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Huaier Granule
What this could lead to
If it works, this could offer a new way to manage proteinuria as a side effect of cancer treatment, potentially improving quality of life for breast cancer patients.
What could go wrong
This is a small Phase 2 trial, so results are preliminary. The granule may not reduce proteinuria better than standard care, and its long-term safety is not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \*\*Inclusion Criteria\*\* 1. Female patients aged 18-75 years. 2. Histopathologically confirmed diagnosis of breast cancer. 3. Currently receiving or having a prior history of immunotherapy and/or anti-angiogenic therapy. 4. First-time detection of proteinuria on urinalysis, graded as +, ++, or +++. 5. 24-hour urinary protein quantification between 0.15g and 3.5g (exclusive). 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 7. Karnofsky Performance Status (KPS) score ≥70. 8. No prior treatment with Huaier Granule within one month before enrollment. 9. Life expectancy of at least 6 months. 10. Willingness to voluntarily participate in the study and provision of signed informed consent. Exclusion Criteria: * \*\*Exclusion Criteria\*\* 1. Known history of chronic kidney disease (eGFR \<60 ml/min/1.73m²) or diabetic nephropathy. 2. Proteinuria attributed to other diseases, including but not limited to primary renal disease, hypertension, urinary tract infection, systemic lupus erythematosus, or multiple myeloma. 3. Current use of ACEI/ARB medications (unless the dosage has been stable for ≥4 weeks prior to enrollment). 4. Known allergy, contraindication, or specific precaution to any component of Huaier Granule. 5. Women who are pregnant, breastfeeding, or planning to conceive. 6. Concurrent participation in any other clinical trial investigating medications for proteinuria. 7. Any other condition that, in the judgment of the investigator, would make the patient unsuitable for participation in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer patients are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer patients Proteinuria

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.